Sepio Capital, LP - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 352 filers reported holding BIO-TECHNE CORP in Q1 2019. The put-call ratio across all filers is 1.52 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Sepio Capital, LP ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$562,122
-16.6%
8,2580.0%0.05%
-10.9%
Q2 2023$674,101
+7.1%
8,258
-2.6%
0.06%
-5.2%
Q1 2023$629,205
-14.5%
8,481
-4.5%
0.06%
-9.4%
Q4 2022$735,643
+14.2%
8,876
+291.2%
0.06%0.0%
Q3 2022$644,000
-20.6%
2,269
-3.0%
0.06%
-21.0%
Q2 2022$811,000
-20.4%
2,340
-0.6%
0.08%
-9.0%
Q1 2022$1,019,000
-31.4%
2,354
-18.0%
0.09%
-19.1%
Q4 2021$1,485,000
-8.2%
2,871
-14.0%
0.11%
-17.3%
Q3 2021$1,617,000
+1.8%
3,337
-5.4%
0.13%
+1.5%
Q2 2021$1,588,000
+17.8%
3,527
-0.1%
0.13%
+5.6%
Q1 2021$1,348,000
-3.6%
3,529
-19.8%
0.12%
+2.5%
Q4 2020$1,398,000
+36.9%
4,402
+6.8%
0.12%
+9.0%
Q3 2020$1,021,000
-6.2%
4,1220.0%0.11%
-13.3%
Q2 2020$1,088,000
+61.2%
4,122
+15.9%
0.13%
+43.8%
Q1 2020$675,000
-13.8%
3,558
-0.2%
0.09%
+20.3%
Q4 2019$783,000
+8.3%
3,565
-3.5%
0.07%
-1.3%
Q3 2019$723,000
-0.4%
3,696
+6.1%
0.08%
-23.5%
Q2 2019$726,000
-47.2%
3,482
-49.8%
0.10%
+1.0%
Q1 2019$1,376,000
+87.0%
6,934
+36.3%
0.10%
+79.6%
Q4 2018$736,0005,0880.05%
Other shareholders
BIO-TECHNE CORP shareholders Q1 2019
NameSharesValueWeighting ↓
Ownership Capital B.V. 840,131$363,810,0004.80%
Montanaro Asset Management Ltd 89,950$38,952,0004.80%
Sandhill Capital Partners LLC 109,939$47,608,0004.09%
Brown Capital Management 918,328$397,673,0003.96%
STONE RUN CAPITAL, LLC 22,325$9,668,0003.57%
DF DENT & CO INC 686,484$297,275,0003.42%
Westwind Capital 27,741$12,013,0003.23%
MAIRS & POWER INC 657,962$284,924,0002.87%
Summit Creek Advisors LLC 58,133$25,174,0002.85%
Pembroke Management, LTD 76,250$33,019,0002.76%
View complete list of BIO-TECHNE CORP shareholders